Vomiting News and Research RSS Feed - Vomiting News and Research

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.
Turing Pharmaceuticals emphasizes continued availability of Daraprim

Turing Pharmaceuticals emphasizes continued availability of Daraprim

Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases and conditions, today emphasizes the continued availability of Daraprim and cautions healthcare providers of proposed alternatives to Daraprim. [More]
Bridion injection approved to reverse effects of neuromuscular blocking drugs used during certain types of surgery

Bridion injection approved to reverse effects of neuromuscular blocking drugs used during certain types of surgery

The U.S. Food and Drug Administration today approved Bridion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, which are used during certain types of surgery in adults. [More]
Nutritionist offers myriad methods to help people eat during cancer treatment

Nutritionist offers myriad methods to help people eat during cancer treatment

Ernestine Trujillo, MS, RD, LD, plays an important role in helping people through their cancer treatment: she helps them to eat. Eating keeps their strength up so that they can get through treatment. But eating during cancer treatment isn't always easy. Trujillo, a Senior Clinical Nutritionist at the University of New Mexico Comprehensive Cancer Center, offers myriad methods to help people get the nutrition they need. [More]
FDA approves Vistogard (uridine triacetate) for emergency treatment of chemotherapy overdose

FDA approves Vistogard (uridine triacetate) for emergency treatment of chemotherapy overdose

The U.S. Food and Drug Administration today approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments. [More]

Easy and fast way to bring relief to nauseated patients in emergency department

Nauseated patients in the emergency department who sniffed pads saturated with isopropyl alcohol were twice as likely to obtain relief from their symptoms as nauseated patients who sniffed pads saturated with saline solution, according to a study published online today in Annals of Emergency Medicine ("Isopropyl Alcohol Nasal Inhalation for Nausea in the Emergency Department: A Randomized Controlled Trial"). [More]
Kanuma approved as first treatment for patients with LAL deficiency

Kanuma approved as first treatment for patients with LAL deficiency

Today, the U.S. Food and Drug Administration approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency. [More]
Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing that treatment with NINLARO (ixazomib) capsules is effective in extending progression free survival (PFS) with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma. [More]
People who experience persistent heartburn despite over-the-counter treatments need to check with their doctors

People who experience persistent heartburn despite over-the-counter treatments need to check with their doctors

If Thanksgiving makes you wince at the thought of impending heartburn pain, you are probably not alone. But if you experience heartburn more than twice a week despite over-the-counter treatments, a Jefferson expert wants you to check with your doctor. Gastroesophageal Reflux Disease (GERD) Awareness Week is observed each year during the week of Thanksgiving, a fitting time as Americans prepare to indulge in the holiday season. [More]
Compared to monotherapy combination of pills for advanced skin cancer extends survival

Compared to monotherapy combination of pills for advanced skin cancer extends survival

The combination of cobimetinib and Zelboraf® (vemurafenib) has been shown to extend the lives of previously untreated patients with advanced skin cancer to nearly two years (22.3 months) [More]
Ninlaro (ixazomib) approved to treat people with multiple myeloma

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy. [More]
NICE recommends Xofigo (radium-223 dichloride) for patients with advanced prostate cancer

NICE recommends Xofigo (radium-223 dichloride) for patients with advanced prostate cancer

The National Institute for Health and Care Excellence today issued its Final Appraisal Determination (FAD) recommending Xofigo (radium-223 dichloride) for use on the NHS in England as an option for treating adult men, with hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, who have received previous docetaxel therapy. [More]

Medical researchers use social media to study harmful side effects of narcotics medication

Harnessing the power of social media, medical researchers have sifted through more than two billion tweets and online posts to study the harmful side effects of narcotics medication taken for chronic pain. [More]
Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). [More]
FDA approves Narcan nasal spray to prevent or reverse effects of opioid overdose

FDA approves Narcan nasal spray to prevent or reverse effects of opioid overdose

Today the U.S. Food and Drug Administration approved Narcan nasal spray, the first FDA-approved nasal spray version of naloxone hydrochloride, a life-saving medication that can stop or reverse the effects of an opioid overdose. Opioids are a class of drugs that include prescription medications such as oxycodone, hydrocodone, and morphine, as well as the illegal drug heroin. [More]
Bullies and victims at risk for eating disorders

Bullies and victims at risk for eating disorders

Being bullied in childhood has been associated with increased risk for anxiety, depression and even eating disorders. But according to new research, it's not only the victims who could be at risk psychologically, but also the bullies themselves. [More]
Personalized approach to treating side-effects of chemotherapy better for cancer patients

Personalized approach to treating side-effects of chemotherapy better for cancer patients

A new research study led by Dr. Mark Clemons, oncologist and associate cancer research scientist at The Ottawa Hospital, has shown that a personalized approach to treating one of the most expected side-effects of chemotherapy is far more effective than the existing "one size fits all" set of guidelines. [More]
Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

The U.S. Food and Drug Administration today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can't be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation). [More]
Orlando Health researchers develop blood test that can detect signs of concussion in children

Orlando Health researchers develop blood test that can detect signs of concussion in children

Researchers at Orlando Health have developed a blood test that can detect even the most subtle signs of a concussion in children, correctly identifying the presence of traumatic brain injuries 94 percent of the time in a recent study. [More]
Gastric balloon in a pill helps patients lose weight without surgery or endoscopy

Gastric balloon in a pill helps patients lose weight without surgery or endoscopy

A new gastric balloon that can be swallowed like a pill and then filled while in the stomach, helped patients lose more than 37 percent of their excess weight over four months, according to new research presented here at ObesityWeek 2015, the largest international event focused on the basic science, clinical application and prevention and treatment of obesity. The weeklong conference is hosted by the American Society for Metabolic and Bariatric Surgery (ASMBS) and The Obesity Society (TOS). [More]
Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene. [More]
Advertisement
Advertisement